Results 51 to 60 of about 6,396 (177)

Inherited microcytic anemias due to disorders of iron and heme metabolism: An updated clinical review

HemaSphere, Volume 10, Issue 9, September 2026.
Abstract Microcytic anemia is among the most common hematological abnormalities in clinical practice and is usually attributable to iron deficiency, thalassemia traits, or anemia of inflammation. A small but clinically important subset of patients, however, has inherited disorders of iron metabolism or heme synthesis presenting with persistent ...
Alexandros Makis, Ioanna Saougou, Eleftheria Hatzimichael   +2 more
wiley   +1 more source

Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition

, 2019
Thalassemia patients are susceptible to both iron overload and thromboembolism. Deferiprone is an iron chelator that shows an antiplatelet activity and thus may alleviate platelet hyperactivation in thalassemia.
Benjaporn Akkawat (7111757), Ngan Thi Tran (7111754), Ponlapat Rojnuckarin (4693228), Noppawan Phumala Morales (7111760), Rataya Luechapudiporn (7111763)   +4 more
core   +1 more source

Generation of reactive oxygen species by hydroxypyridone compound/iron complexes

Redox Report, 2020
Objectives: Prooxidant properties of iron-binding hydroxypyridone compounds including deferiprone and mimosine were analyzed. Methods: Hydroxypyridone/iron-dependent production of reactive oxygen species was evidenced by the inactivation of aconitase ...
Keiko Murakami, Masataka Yoshino
doaj   +1 more source

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production

Cells, 2020
Deferiprone (DFP), also known as Ferriprox, is an FDA-approved, orally active, iron chelator that is currently used clinically for the treatment of iron-overload, especially in thalassaemia major.
Marco Fiorillo, Fanni Tóth, Matteo Brindisi, Federica Sotgia, Michael P. Lisanti   +4 more
doaj   +1 more source

Deferiprone increases endothelial nitric oxide synthase phosphorylation and nitric oxide production [PDF]

, 2018
Iron chelation can improve endothelial function. However, effect on endothelial function of deferiprone has not been reported. We hypothesized deferiprone could promote nitric oxide (NO) production in endothelial cells.
Rattanawonsakul , Krit, Vivithanaporn, Pornpun, Thanaporn Sriwantana, Nathawut Sibmooh, Sibmooh, Nathawut, Sirada Srihirun, Pornpun Vivithanaporn, Krit Rattanawonsakul, Paiboonsukwong, Kittiphong, Sriwantana, Thanaporn, Kittiphong Paiboonsukwong, Srihirun, Sirada   +11 more
core   +1 more source

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies

Anemia, 2013
Iron overload in hemoglobinopathies is secondary to blood transfusions, chronic hemolysis, and increased iron absorption and leads to tissue injury requiring the early use of chelating agents.
Alexandros Makis, Nikolaos Chaliasos, Sapfo Alfantaki, Paraskevi Karagouni, Antigone Siamopoulou   +4 more
doaj   +1 more source

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

Journal of Cardiovascular Magnetic Resonance, 2011
Background Thalassaemia major (TM) patients need regular blood transfusions that lead to accumulation of iron and death from heart failure. Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in ...
Gotsis Efstathios D, Aessopos Athanassios, Piga Antonio, Ladis Vasili, Karagiorga Markissia, Berdoukas Vasili, Alam Mohammed H, Carpenter John, Alpendurada Francisco, Smith Gillian C, Tanner Mark A, Westwood Mark A, Galanello Renzo, Roughton Michael, Pennell Dudley J   +14 more
doaj   +1 more source

Iron‐Sulfur Cluster Targeting: A Novel Perspective for Treating Alcohol‐Related Lipid Metabolic Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
Alcohol metabolism induces structural instability of iron‐sulfur clusters through ROS‐mediated oxidative damage and direct covalent modification of acetaldehyde. The iron‐sulfur cluster deficiency drives metabolic reprogramming by inactivating aconitase, accumulating succinate, and impairing tRNA thiolation, thereby promoting hepatic steatosis ...
Li Xu, Zhenyang Xu, Chenli Su, Yanqian Zhao, Linjing Qiang, Xiayong Jing, Yuxiang Sun   +6 more
wiley   +1 more source

Deferiprone, an Iron Chelator, is Preventive and Therapeutic in Experimental Crescentic Glomerulonephritis

, 2017
Crescentic glomerulonephritis represents the most severe form of antibody-mediated glomerulonephritis. It is an important cause of renal dysfunction worldwide and there is a need for more effective treatment.
Tai-Di Chen, Jeong-Hun Ko, H. Terence Cook, Jacques Behmoaras, Charles D. Pusey, Maria Prendecki, Stephen P. McAdoo   +6 more
core   +1 more source

From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis

Journal of Inherited Metabolic Disease, Volume 49, Issue 5, September 2026.
ABSTRACT Coenzyme A (CoA) biosynthesis is a conserved, dynamically regulated pathway essential for mitochondrial energy production, fatty acid oxidation, lipid biosynthesis and protein acylation. Biallelic variants in PANK2, PPCS, PPCDC, and COASY cause rare inborn errors of CoA biosynthesis, associated with markedly different clinical phenotypes ...
Ivano Di Meo, Yair Anikster, Valeria Tiranti, Arcangela Iuso   +3 more
wiley   +1 more source